Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma

International Journal of Cancer

Volumn 133, Issue 12, 2013, Pages 2884-2894

  De Vos Van Steenwijk, P J ^a   Ramwadhdoebe, T H ^a   Goedemans, R ^a   Doorduijn, E M ^a   Van Ham, J J ^a   Gorter, A ^a   Van Hall, T ^a   Kuijjer, M L ^a   Van Poelgeest, M I E ^a   Van Der Burg, S H ^a   Jordanova, E S ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cervical cancer; myeloid cells; survival; tumor microenvironment

Indexed keywords

CD14 ANTIGEN; CD163 ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; BONE MARROW CELL; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL COUNT; CELL FUNCTION; CELL INFILTRATION; CELL MATURATION; CELL POPULATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CLINICAL FEATURE; COHORT ANALYSIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL PARAMETERS; INDEPENDENT VARIABLE; MACROPHAGE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; POLARIZATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; UTERINE CERVIX CARCINOMA;

CERVICAL CANCER; MYELOID CELLS; SURVIVAL; TUMOR MICROENVIRONMENT;

ANTIGENS, CD14; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MIDDLE AGED; MYELOID CELLS; PROGNOSIS; TUMOR MICROENVIRONMENT; UTERINE CERVICAL NEOPLASMS;

EID: 84885675500     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28309     Document Type: Article

References (50)

1. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-8.
2. Jordanova ES, Gorter A, Ayachi O, et al. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 2008; 14: 2028-35.
3. van der Burg SH, Melief CJ,. Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol 2011; 23: 252-7.
4. de Vos van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH, et al. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res 2010; 70: 2707-17.
5. Piersma SJ, Welters MJ, van der Hulst JM, et al. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer 2008; 122: 486-94.
6. Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007; 67: 354-61.
7. Bontkes HJ, de Gruijl TD, Walboomers JM, et al. Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br J Cancer 1997; 76: 1353-60.
8. Karim R, Jordanova ES, Piersma SJ, et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009; 15: 6341-7.
9. Gooden M, Lampen M, Jordanova ES, et al. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes. Proc Natl Acad Sci U S A 2011; 108: 10656-61.
10. Mehta AM, Jordanova ES, Kenter GG, et al. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 2008; 57: 197-206.
11. Heusinkveld M, Welters MJ, van Poelgeest MI, et al. The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int J Cancer 2011; 128: 379-89.
12. Nedergaard BS, Ladekarl M, Nyengaard JR, et al. A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecol Oncol 2008; 108: 106-11.
13. Gordon S, Taylor PR,. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-64.
14. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V,. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-68.
15. Gottfried E, Kreutz M, Mackensen A,. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev 2008; 19: 65-77.
16. Heusinkveld M, van der Burg SH,. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011; 9: 216.
17. Al-Saleh W, Delvenne P, Arrese JE, et al. Inverse modulation of intraepithelial Langerhans' cells and stromal macrophage/dendrocyte populations in human papillomavirus-associated squamous intraepithelial lesions of the cervix. Virchows Arch 1995; 427: 41-8.
18. Davidson B, Goldberg I, Kopolovic J,. Inflammatory response in cervical intraepithelial neoplasia and squamous cell carcinoma of the uterine cervix. Pathol Res Pract 1997; 193: 491-5.
19. Davidson B, Goldberg I, Gotlieb WH, et al. Macrophage infiltration and angiogenesis in cervical squamous cell carcinoma-clinicopathologic correlation. Acta Obstet Gynecol Scand 1999; 78: 240-4.
20. Zijlmans HJ, Fleuren GJ, Baelde HJ, et al. Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma. Cancer 2007; 109: 556-65.
21. Srivani R, Nagarajan B,. A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer 2003; 13: 331-9.
22. Huang M, Chen Q, Xiao J, et al. Prognostic significance of cyclooxygenase-2 in cervical cancer: a meta-analysis. Int J Cancer 2012; 132: 363-73.
23. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 2011; 187: 1157-65.
24. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
25. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 2011; 187: 1157-65.
26. Figel AM, Brech D, Prinz PU, et al. Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations. Am J Pathol 2011; 179: 436-51.
27. Andrews RG, Torok-Storb B, Bernstein ID,. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 1983; 62: 124-32.
28. Van GH, Delputte PL, Nauwynck HJ,. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol 2010; 47: 1650-60.
29. Maniecki MB, Moller HJ, Moestrup SK, et al. CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology 2006; 211: 407-17.
30. de Boer MA, Jordanova ES, van Poelgeest MI, et al. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts. Int J Cancer 2007; 121: 2711-15.
31. Kloth JN, Gorter A, Fleuren GJ, et al. Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol 2008; 215: 222-30.
32. Schrevel M, Karim R, ter Haar NT, et al. CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients. Br J Cancer 2012; 106: 1520-5.
33. Schrevel M, Gorter A, Kolkman-Uljee SM, et al. Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer. Mod Pathol 2011; 24: 720-8.
34. Kuijjer ML, Namlos HM, Hauben EI, et al. mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. BMC Med Genomics 2011; 4: 66.
35. Ruiter DJ, Ferrier CM, van Muijen GN, et al. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer 1998; 34: 1334-40.
36. Kobayashi A, Weinberg V, Darragh T, et al. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol 2008; 1: 412-20.
37. Inaba T, Ino K, Kajiyama H, et al. Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecol Oncol 2010; 117: 423-8.
38. Singh N, Arif S,. Histopathologic parameters of prognosis in cervical cancer-a review. Int J Gynecol Cancer 2004; 14: 741-50.
39. Thomas GM,. Adjuvant therapy after primary surgery for stage I-IIA carcinoma of the cervix. J Natl Cancer Inst Monogr 1996;21: 77-83.
40. Snijders-Keilholz A, Hellebrekers BW, Zwinderman AH, et al. Adjuvant radiotherapy following radical hysterectomy for patients with early-stage cervical carcinoma (1984-1996). Radiother Oncol 1999; 51: 161-7.
41. Kenter GG, Hellebrekers BW, Zwinderman KH, et al. The case for completing the lymphadenectomy when positive lymph nodes are found during radical hysterectomy for cervical carcinoma. Acta Obstet Gynecol Scand 2000; 79: 72-6.
42. Ohri CM, Shikotra A, Green RH, et al. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 2009; 33: 118-26.
43. Heys SD, Stewart KN, McKenzie EJ, et al. Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer. Breast Cancer Res Treat 2012; 135: 539-48.
44. Kinouchi M, Miura K, Mizoi T, et al. Infiltration of CD14-positive macrophages at the invasive front indicates a favorable prognosis in colorectal cancer patients with lymph node metastasis. Hepatogastroenterology 2011; 58: 352-8.
45. Kinouchi M, Miura K, Mizoi T, et al. Infiltration of CD40-positive tumor-associated macrophages indicates a favorable prognosis in colorectal cancer patients. Hepatogastroenterology 2012; 60:doi:10.5754/hge12372.
46. Ma J, Liu L, Che G, et al. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010; 10: 112.
47. Diao J, Mikhailova A, Tang M, et al. Immunostimulatory conventional dendritic cells evolve into regulatory macrophage-like cells. Blood 2012; 119: 4919-27.
48. Kodumudi KN, Woan K, Gilvary DL, et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16: 4583-94.
49. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331: 1612-16.
50. Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-21.